Literature DB >> 7720176

The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

A V Boddy1, M Cole, A D Pearson, J R Idle.   

Abstract

It has often been reported that the oxazaphosphorines ifosfamide and cyclophosphamide induce their own metabolism. This phenomenon was studied in 21 paediatric patients over 35 courses of therapy. All patients received 9 gm-2 of ifosfamide as a continuous infusion over 72 h. Plasma concentrations of parent drug and of the major metabolite in plasma, 3-dechloroethylifosfamide (3DC) were determined, using a quantitative thin-layer chromatography (TLC) technique. A one-compartment model was fitted simultaneously to both ifosfamide and 3DC data. The model included a time-dependent clearance term, increasing asymptotically from an initial value to a final induced clearance and characterised by a first-order rate constant. A time lag, before induction of clearance began, was determined empirically. Metabolite kinetics were characterised by an elimination rate constant for the metabolite and a composite parameter comprising a formation clearance, proportional to the time-dependent clearance of parent drug, divided by the volume of distribution of the metabolite. Thus, the parameters to estimate were the volume of distribution of parent drug (V), initial clearance (Cli), final clearance (Cls), the rate constant for changing clearance (Kc), the elimination rate constant for the metabolite (Km) and Vm/fm, the metabolite volume of distribution divided by the fractional clearance to 3DC. The model of drug and metabolite kinetics produced a good fit to the data in 22 of 31 courses. In a further 4 courses an auto-inductive model for parent drug alone could be used. In the remaining courses, auto-induction could be demonstrated, but there were insufficient data to fit the model. For some patients this was due to a long time lag (up to 54 h) relative to the infusion time. The time lag varied from 6 to 54 (median, 12)h and values for the other parameters were Cli, 3.27 +/- 2.52 lh-1 m-2, Cls, 7.50 +/- 3.03 lh-1 m-2, V, 22.0 +/- 11.0 1 m-2, Kc, 0.086 +/- 0.074 h-1; Km, 0.159 +/- 0.077 h-1 and Vm/fm, 104 +/- 82 1m-2. The values of Kc correspond to a half-life of change in clearance ranging from 2 to 157 h, although for the majority of the patients the half-life was less than 7 h and a new steady-state level was achieved during the 72 h infusion period. This model provides insight into the time course of enzyme induction during ifosfamide administration, which may continue for up to 10 days in some protocols.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720176     DOI: 10.1007/BF00685732

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  32 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Effect of cancer chemotherapy on dapsone N-acetylation in man.

Authors:  P A Philip; P G Harper; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Mechanisms of cyclophosphamide action on hepatic P-450 expression.

Authors:  G A LeBlanc; D J Waxman
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

4.  Kinetic models of induction: I. Persistence of the inducing substance.

Authors:  F P Abramson
Journal:  J Pharm Sci       Date:  1986-03       Impact factor: 3.534

5.  Dechloroethylation of ifosfamide and neurotoxicity.

Authors:  M P Goren; R K Wright; C B Pratt; F E Pell
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.

Authors:  D Walker; J P Flinois; S C Monkman; C Beloc; A V Boddy; S Cholerton; A K Daly; M J Lind; A D Pearson; P H Beaune
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

7.  Effects of cimetidine on carbamazepine auto- and hetero-induction in man.

Authors:  G J Macphee; G G Thompson; G Scobie; E Agnew; B K Park; T Murray; K E McColl; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

8.  Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.

Authors:  X J Zhou; X R Zhou-Pan; T Gauthier; M Placidi; P Maurel; R Rahmani
Journal:  Biochem Pharmacol       Date:  1993-02-24       Impact factor: 5.858

9.  Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.

Authors:  C L Denlinger; K K Stryker; L B Slusher; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

10.  Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Authors:  M I Graham; I C Shaw; R L Souhami; B Sidau; P G Harper; A E McLean
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more
  20 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

3.  Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Authors:  T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 5.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

6.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

7.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

8.  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Authors:  T Kerbusch; J de Kraker; R A Mathĵt; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.

Authors:  M P Di Marco; I W Wainer; C L Granvil; G Batist; M P Ducharme
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

10.  Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

Authors:  P Hamberg; N Steeghs; W J Loos; D van de Biessen; M den Hollander; M Tascilar; J Verweij; H Gelderblom; S Sleijfer
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.